Qualigen Therapeutics, Inc. (QLGN)
NASDAQ: QLGN · Real-Time Price · USD
2.903
-0.047 (-1.60%)
At close: Jul 24, 2025, 4:00 PM
2.910
+0.007 (0.25%)
After-hours: Jul 24, 2025, 6:49 PM EDT
Company Description
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States.
The company’s lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1 clinical trial for the treatment of pancreatic cancer and other solid tumors.
It is also developing Pan-RAS, for the treatment of advanced solid tumors, which is in a preclinical stage.
Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Qualigen Therapeutics, Inc.
| Country | United States |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Kevin Richardson |
Contact Details
Address: 5857 Owens Avenue, Suite 300 Carlsbad, California 92008 United States | |
| Phone | 760 452 8111 |
| Website | qlgntx.com |
Stock Details
| Ticker Symbol | QLGN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001460702 |
| CUSIP Number | 74754R103 |
| ISIN Number | US74754R3012 |
| Employer ID | 26-3474527 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kevin A. Richardson II | Interim Chief Executive Officer, Interim Chief Financial Officer and Chairman of the Board |
| Michael S. Poirier | Chief Operating Officer |
| Robert W. Campbell Becher | President and Director |
| Christopher L. Lotz | Vice President of Finance and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 21, 2025 | 10-Q | Quarterly Report |
| Jul 16, 2025 | 8-K | Current Report |
| Jun 30, 2025 | 10-K | Annual Report |
| Jun 24, 2025 | 8-K | Current Report |
| May 19, 2025 | 8-K | Current Report |
| May 1, 2025 | 8-K | Current Report |
| Apr 1, 2025 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Jan 28, 2025 | 8-K | Current Report |
| Dec 26, 2024 | 8-K | Current Report |
| Dec 19, 2024 | EFFECT | Notice of Effectiveness |